Short description
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics.
Description
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neural cells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes are differentiated into beta cells for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system.
Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells. It produces a number of human cell and tissue systems that constitute screening platforms to search for agonists or antagonists of specific biological processes, with the aim of developing safe drugs.
Kadimastem is based in Nes Ziona, Israel.
Last funding
Nopepepe
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Ness Ziona, HaMerkaz, Israel, Asia
Founded on
January 1, 2009
Exited on
June 27, 2013
Went public on
June 27, 2013
Stock symbol
KDST
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Absolutely Noaccess, No Way, Nopepepe, Absolutely Noaccess, No Way, Noway Youcantaccess, Blurry Noaccess
Sign in for full access
Founders
Michel Revel, Yossi Ben Yosef